SABBY MANAGEMENT LLC 13D and 13G filings for Virpax Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-01-02 10:24 am Unchanged | 2023-12-31 | 13G | Virpax Pharmaceuticals, Inc. VRPX | SABBY MANAGEMENT LLC | 0 0.000% | 0 (Unchanged) | Filing |
| 2024-01-02 10:11 am Sale | 2023-12-31 | 13G | Virpax Pharmaceuticals, Inc. VRPX | SABBY MANAGEMENT LLC | 0 0.000% | -3,953 (Position Closed) | Filing |
| 2023-01-10 1:36 pm Purchase | 2022-12-31 | 13G | Virpax Pharmaceuticals, Inc. VRPX | SABBY MANAGEMENT LLC | 3,953 11.000% | 445 (+12.70%) | Filing |
| 2022-01-04 11:31 am Sale | 2021-12-31 | 13G | Virpax Pharmaceuticals, Inc. VRPX | SABBY MANAGEMENT LLC | 3,507 11.000% | -493 (-12.32%) | Filing |
| 2021-09-23 07:29 am Purchase | 2021-09-14 | 13G | Virpax Pharmaceuticals, Inc. VRPX | SABBY MANAGEMENT LLC | 4,000 11.000% | 4,000 (New Position) | Filing |